Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
With 267 million tobacco users, improving access to evidence-based cessation tools is seen as critical
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
VESCOP, ENTOD Pharmaceuticals, and APTI-MSB host the event to bridge lab-to-clinic gap in eye care
Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research
Genome editing holds extraordinary promise for treating previously incurable genetic diseases
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
